GRFS (Grifols) Other Operating Expense: $157 Mil (TTM As of Mar. 2026)


GRFS Grifols SA GRFS
82 GF Score
Price $7.16
GF Value $8.71
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Grifols Other Operating Expense?

Grifols GRFS +1.06% 82 Other Operating Expense is $157 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.71 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Grifols's Other Operating Expense for the three months ended in Mar. 2026 was $0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $157 Mil.

Grifols's quarterly Other Operating Expense increased from Sep. 2025 ($-1 Mil) to Dec. 2025 ($140 Mil) but then declined from Dec. 2025 ($140 Mil) to Mar. 2026 ($0 Mil).

Grifols's annual Other Operating Expense increased from Dec. 2023 ($113 Mil) to Dec. 2024 ($117 Mil) and increased from Dec. 2024 ($117 Mil) to Dec. 2025 ($139 Mil).

Grifols Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Grifols's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Other Operating Expense Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.42 69.73 113.41 117.28 139.34

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 17.65 -0.50 139.85 0.00
GRFS
82GF Score
Grifols SA GRFS
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $157 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $157 Mil mean?
Grifols (GRFS) has a Other Operating Expense of $157 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Grifols and its competitors.
Is Grifols' Other Operating Expense too high?
Grifols' current Other Operating Expense is $157 Mil. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Other Operating Expense compare to LLY and JNJ?
Grifols' Other Operating Expense of $157 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Grifols and its competitors. Grifols's current Other Operating Expense is $157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.71, compared to a current price of $7.16 — trading 17.8% below its estimated fair value. The current Other Operating Expense is $157 Mil. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Grifols (GRFS), the current Other Operating Expense is $157 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.16 is trading 17.8% below its estimated GF Value™ of $8.71. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Other Operating Expense: $157 Mil
  • GF Value™: $8.71 vs. price of $7.16 (17.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for GRFS

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$8.71
GF Value